{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:21:07Z","timestamp":1760059267294,"version":"build-2065373602"},"reference-count":12,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Kidney transplantation remains the most effective method of renal replacement therapy. Living donor transplantation offers several advantages\u2014reduced cardiovascular risk, better graft survival, and preemptive intervention. However, donor obesity is a growing concern, as it is usually associated with perioperative and long-term complications, which can affect donor eligibility. Bariatric surgery is a standard recommendation for patients with a BMI over 35 kg\/m2. There are limited data on the use of pharmacological agents for weight reduction in kidney donors. This case presents a successful conservative treatment with GLP-1 receptor agonist in an obese woman wishing to donate a kidney to her son. Case Presentation: We are presenting the case of a 63-year-old woman with grade II obesity who was initially denied being a kidney donor to her son because of her weight. Under these circumstances, she underwent comprehensive lifestyle modification in the cardio-obesitology clinic (caloric restriction, physical activity, and pharmacological treatment with liraglutide). During the 3-month follow-up, she decreased her BMI to 33.4 kg\/m2, and subsequent examinations confirmed no surgical contraindications to donating a kidney. Despite hematuria, biopsy and genetic testing revealed a benign carrier condition of Alport syndrome, which, without proteinuria or renal impairment, allowed successful kidney donation. Conclusions: This case demonstrates that conservative pharmacological treatment for body weight reduction with GLP-1 receptor agonists may be an alternative to bariatric surgery for selected obese kidney donor candidates. The presented case highlights the importance of a multidisciplinary and personalized approach.<\/jats:p>","DOI":"10.3390\/reports8020085","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T03:57:18Z","timestamp":1748923038000},"page":"85","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improving the Quality of Two Lives by Treating Obesity"],"prefix":"10.3390","volume":"8","author":[{"given":"Norbert","family":"Nagy","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5156-5226","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Kleinov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia"},{"name":"Department of Transplantation and Nephrology, University Hospital Martin, Koll\u00e1rova 2, 036 01 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-4134","authenticated-orcid":false,"given":"Martin Jozef","family":"P\u00e9\u010d","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5561-2560","authenticated-orcid":false,"given":"Matej","family":"Samo\u0161","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8246-4268","authenticated-orcid":false,"given":"Ivana","family":"Dedinsk\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia"},{"name":"Department of Transplantation and Nephrology, University Hospital Martin, Koll\u00e1rova 2, 036 01 Martin, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, April 20). The Challenge of Obesity. 23 February 2024. Available online: https:\/\/www.who.int\/europe\/news-room\/fact-sheets\/item\/the-challenge-of-obesity."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ckj\/sfac216","article-title":"Donor obesity and weight gain after transplantation: Two still overlooked threats to long-term graft survival","volume":"16","author":"Kanbay","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_4","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2020). KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation, 104, S11\u2013S103."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1517\/17460441.2015.1044966","article-title":"Latest approaches for the treatment of obesity","volume":"10","author":"Jackson","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1590\/S1677-55382007000300010","article-title":"Laparoscopic live donor nephrectomy in patients surgically treated for morbid obesity","volume":"33","author":"Branco","year":"2007","journal-title":"Int. Braz. J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ndt\/gfm511","article-title":"A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease","volume":"23","author":"Cook","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.jrn.2015.05.001","article-title":"Participation in a structured weight loss program and all-cause mortality and cardiovascular morbidity in obese patients with chronic kidney disease","volume":"25","author":"MacLaughlin","year":"2015","journal-title":"J. Ren. Nutr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, double-blind, placebo-controlled study of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Greenway","year":"2013","journal-title":"Obesity"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/2\/85\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:20Z","timestamp":1760031980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/2\/85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["reports8020085"],"URL":"https:\/\/doi.org\/10.3390\/reports8020085","relation":{},"ISSN":["2571-841X"],"issn-type":[{"type":"electronic","value":"2571-841X"}],"subject":[],"published":{"date-parts":[[2025,6,3]]}}}